Clinical Trial: Observational Study to Assess the Safety of rhTNK-tPA (Mingfule(R)) vs. Rt-PA (Actilyse(R)) in Treating Acute Ischemic Stroke

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519889) titled 'Observational Study to Assess the Safety of rhTNK-tPA (Mingfule(R)) vs. Rt-PA (Actilyse(R)) in Treating Acute Ischemic Stroke' on March 27.

Brief Summary: This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse(R)) as the control. It is designed to evaluate the safety of intravenous thrombolysis with recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA, Mingfule(R)) compared with rt-PA (Actilyse(R)) in patients with acute ischemic stroke in the real-world setting.

This is a non-interventional observational study with no randomization. Treatment decision...